Targeted Delivery of Bilirubin to Pulmonary Endothelium Mitigates Paraquat-Induced Lung Injury Authors: Mengyuan Cen, Tongyu Li, Xingyu Chen, Jiajin Chen, Weiliang Kong, Qianhua Cao, Zihao Ke, Ke Zhu, Rongbin Qi, Chunlian Huang, Zhilei Pan, Ning Zhu, Chao Cao Published: 2026 ABSTRACT AbstractIntroductionParaquat (PQ) poisoning causes high mortality via acute lung injury (ALI) driven by excessive reactive oxygen species (ROS) in pulmonary microvascular endothelial cells. We developed BR@Lipo-CerTP, a lung-targeted nanotherapeutic using C16-ceramide-binding peptide-modified bilirubin liposomes, to enhance endothelial delivery and treat PQ-induced ALI.MethodsBR@Lipo-CerTP was characterized for physicochemical properties and cellular uptake in pulmonary microvascular endothelial cells (PMVECs). In vitro efficacy was assessed via cytotoxicity, apoptosis, ROS, antioxidant capacity, and mitochondrial function assays in PQ-exposed PMVECs. Multi-omics analysis elucidated therapeutic mechanisms. In vivo efficacy and biosafety were evaluated in a PQ-induced ALI mouse model through survival, histopathology, edema, and toxicity assessments.ResultsBR@Lipo-CerTP exhibited uniform ~120 nm spherical morphology, narrow size distribution, excellent stability, and enhanced PMVEC uptake versus non-targeted liposomes. In vitro, it significantly attenuated PQ-induced cytotoxicity, apoptosis, and ROS accumulation while restoring antioxidant capacity and mitochondrial function. Multi-omics revealed it disrupts a vicious cycle of glutathione depletion, ferroptosis, and NF-κB/NLRP3-driven inflammation, resetting pathological crosstalk between redox homeostasis, regulated cell death, and immune activation. In vivo, BR@Lipo-CerTP markedly improved survival, alleviated pulmonary damage and edema, suppressed oxidative stress and inflammation, with no systemic toxicity.DiscussionPulmonary endothelial-targeted bilirubin delivery effectively mitigates PQ-induced ALI by coordinately regulating redox balance, cell death, and inflammation. This strategy offers a promising nanotherapeutic for PQ poisoning and other ROS-driven pulmonary diseases, highlighting targeted nanomedicine’s potential in toxicological emergencies.Keywords: paraquat, acute lung injury, bilirubin, pulmonary microvascular endothelial cell, ROS Introduction Paraquat (PQ) is a widely used herbicide owing to its low cost and high efficacy; however, its extreme toxicity constitutes a major global health concern, particularly in developing countries.1–3 Despite regulatory restrictions in many regions, PQ exposure remains prevalent, with mortality rates exceeding 50% following ingestion.4,5 The lung is the primary target organ of PQ toxicity, and acute lung injury (ALI), frequently progressing to acute respiratory distress syndrome and pulmonary fibrosis, represents the leading cause of death in PQ poisoning.6,7 To date, no effective antidote or targeted therapeutic strategy is available. Disruption of the alveolar-capillary barrier is both a defining pathological feature and a critical driver of disease progression in PQ-induced ALI.5 Pulmonary microvascular endothelial cells are central to the maintenance of alveolar-capillary barrier integrity and the regulation of vascular permeability.8,9 In the context of PQ exposure, redox cycling within endothelial cells results in persistent ROS overproduction, rendering these cells particularly vulnerable to oxidative stress.10 ROS-induced lipid peroxidation disrupts plasma membrane integrity, while oxidative modification of cytoskeletal and junctional proteins, including vascular endothelial cadherin (VE-cadherin), zonula occludens-1 (ZO-1), and occludin, which leads to disassembly of intercellular junctions. Concurrently, mitochondrial oxidative damage results in ATP depletion and triggers endothelial apoptosis or necrosis.11,12 In addition, ROS activate pro-inflammatory signaling pathways such as nuclear factor-κB (NF-κB), promoting the expression of cytokines and adhesion molecules.13,14 Collectively, these processes drive endothelial dysfunction and markedly increase pulmonary microvascular permeability, leading to vascular leakage, pulmonary edema, and thereby accelerating alveolar-capillary barrier failure. Beyond its traditional recognition as the end product of heme catabolism, bilirubin (BR) is increasingly appreciated as an endogenous cytoprotective molecule with potent antioxidant and anti-inflammatory properties. Growing evidence has demonstrated that hypobilirubinemia is significantly associated with cardiovascular, brain-related and other complications.15,16 In contrast, mildly elevated unconjugated hyperbilirubinemia has been reported to exert protective effects against cardiovascular disease, diabetes, and obesity in adults, as well as asthma in children.17–19 Mechanistically, BR confers protection against oxidative stress by directly scavenging selected ROS, particularly peroxyl radicals and superoxide, inhibiting lipid peroxidation, and modulating redox-sensitive signaling pathways, thereby alleviating oxidative stress-induced cellular damage.20,21 In addition, BR has been shown to suppress inflammatory responses by inhibiting NF-κB dependent endothelial activation and reducing the production of pro-inflammatory cytokines.22 Given the central role of pulmonary microvascular endothelium in PQ-induced ALI, targeted delivery of BR to lung endothelial cells is expected to substantially enhance its antioxidative and anti-inflammatory effects. Recent research has identified C16-ceramide as a vascular target of a lung-homing peptide. Specifically, a ligand peptide with the sequence CGSPGWVRC has been shown to bind to the surface of primary pulmonary vascular endothelial cells in vitro and to selectively accumulate in the lung vasculature in vivo.23 Thus, we developed a peptide-guided targeting strategy by decorating BR-loaded liposomes with the C16-ceramide-binding peptide (BR@Lipo-CerTP). This modification enables selective recognition and accumulation of the nanocarriers within the pulmonary microvasculature, thereby promoting preferential uptake by injured endothelial cells. By integrating endothelial-specific targeting with liposomal encapsulation, this delivery system overcomes the intrinsic solubility and pharmacokinetic limitations of BR while maximizing its local antioxidative and anti-inflammatory efficacy at the site of injury. Consistently, in a PQ-induced ALI mouse model, we show that i.v. administration of BR@Lipo-CerTP effectively eliminates ROS production and dysfunction of pulmonary vascular endothelial cells, relieves pro-inflammatory response, and improves survival rate without inducing adverse events. Methods and Materials Preparation of BR-Loaded Liposomes Lipid nanoparticles encapsulating the bilirubin (MedChemExpress, NJ, USA, HY-N0323) were fabricated via a nanoprecipitation technique.24,25 In brief, bilirubin was first dissolved in DMSO, while a blend of lipids—consisting of egg phosphatidylcholine (Egg-PC) (AVT Pharmaceutical, Shanghai, China), cholesterol (MeloPEG Technology Inc., Shenzhen, China), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)2000] (DSPE-PEG2k) (MeloPEG Technology Inc., Shenzhen, China) (BR@Lipo) or DSPE-PEG2k-CGSPGWVRC (MeloPEG Technology Inc., Shenzhen, China) (BR@LipoCerTP) at a mass ratio of 35:5:8—was separately dissolved in ethanol. The bilirubin solution and the lipid mixture were then combined and introduced dropwise into 2 mL of deionized water under continuous stirring at room temperature. Following 10 min of stirring, residual organic solvents were removed by dialysis. To determine the encapsulation efficacy (EE) of BR@Lipo and BR@Lipo-CerTP, samples were ultrafiltered using a 100 kDa molecular weight cutoff membrane. The collected retentate was mixed with an equal volume of DMSO, and the BR concentration was analyzed via Thermo Scientific UltiMate 3000 (Thermo Scientific, Waltham, MA, USA). In vitro Drug Release Study The in vitro release profiles of free BR, BR@Lipo, and BR@Lipo-CerTP were evaluated using the dialysis method, with free BR serving as a membrane diffusion control.26 Briefly, 1 mL of each formulation (containing an equivalent amount of BR) was sealed in a pretreated dialysis membrane (MWCO: 14 kDa) and immersed in 100 mL of PBS, pH 7.4 containing 5% DMSO to maintain sink conditions. The release medium was maintained at 37 °C under continuous magnetic stirring at 100 rpm. At predetermined time intervals (1, 2, 4, 8, 12, 24, 48, and 72 h), 1 mL of the external medium was withdrawn and immediately replaced with an equal volume of fresh pre-warmed PBS to maintain a constant volume. The concentration of released BR in the collected samples was quantified by Thermo Scientific UltiMate 3000 (Thermo Scientific, Waltham, MA, USA). Cumulative release percentages were calculated based on the total drug loading determined after complete disruption of the liposomal formulations with methanol. Analysis of Cellular Internalization Preparation of DiI-labeled liposomes: Egg-PC, cholesterol, and DSPE-PEG2k (or DSPE-PEG2k-CGSPGWVRC) were dissolved in ethanol at a mass ratio of 35:5:8. DiI (MedChemExpress, NJ, USA, HY-D0083) dye was then added to this lipid mixture. The resulting solution was introduced dropwise into deionized water as mentioned above. The final concentration of DiI in the liposome dispersion was 1 μM, and the final concentration of DiI applied to the cells was 0.05 μM. The intracellular uptake of BR@Lipo or BR@Lipo-CerTP into PMVECs was assessed using two complementary techniques: fluorescence microscope and flow cytometry. For microscopic evaluation, cells were cultured overnight prior to being exposed to DiI-labeled liposomes for predetermined intervals. Subsequent to incubation, the samples were washed, fixed with methanol, and stained with DAPI to enable nuclear visualization under fluorescence microscope. Parallel experiments for quantitative analysis involved plating a higher density of cells in multi-well plates, treating them with BR@Lipo or BR@Lipo-CerTP, and then processing them into a single-cell suspension for immediate analysis by flow cytometry (BD AccurTM C6 Plus, BD Biosciences, San Jose, CA, USA). Animals Male C57BL/6J mice (6–8 weeks old) were randomly assigned to five experimental groups: Control, PQ (MedChemExpress, NJ, USA, HY-B0864A), PQ + free BR, PQ + BR@Lipo, and PQ + BR@Lipo-CerTP, and were housed under standard laboratory conditions. BR (5 mg/kg) was administered by oral gavage 30 min prior to PQ exposure, whereas BR@Lipo (5 mg/kg, calculated based on BR content) and BR@Lipo-CerTP (5 mg/kg, calculated based on BR content) were administered via tail vein injection 30 min after PQ exposure. For the survival study, PQ was administered intraperitoneally at a dose of 70 mg/kg body weight and mice were monitored every 12 h following PQ injection until 96 h post-administration. For other studies, PQ was administered via intraperitoneal injection at a dose of 50 mg/kg body weight. 48 h later, mice were sacrificed and BALF and lung tissues were collected. All experimental procedures involving animals were approved by the Institutional Animal Care and Use Committee of the Institutional Animal Care and Use Committee (IACUC) of Zhejiang Center of Laboratory Animals (Approval No. ZJCLA-IACUC-20011434) and conducted in strict accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, 8th Edition) and the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals (2020 Edition). Animals were housed under specific pathogen-free conditions with a 12 h light/dark cycle, ambient temperature of 22 ± 2°C, relative humidity of 50 ± 10%, and adlibitum access to standard rodent chow and autoclaved water. At the conclusion of the study or when humane endpoints were reached (e. g., severe weight loss >20%, labored breathing, or lethargy), mice were euthanized by intraperitoneal injection of sodium pentobarbital (150 mg/kg). Lung Target Ability and Biodistribution of BR@Lipo-CerTP in vivo Mice with ALI were intravenously injected with 100 μL of DiR (MedChemExpress, NJ, USA, HY-D1048)-labeled BR@Lipo or BR@Lipo-CerTP, and the content of DiR is both 40 μg/mL. Fluorescent signals of DiR in the heart, liver, spleen, lung, and kidney, of different treated mice were measured by a Xenogen IVIS imaging system in vivo and ex vivo at 12 h after vein injection. Histopathological Examination Lung tissues were collected from mice, fixed in 4% paraformaldehyde overnight, and prepared for histopathological examination. The paraffin-embedded samples were cut into 4 μm sections and stained with hematoxylin and eosin (H&E). Histological features were examined using a microscope. Lung Wet-to-Dry Weight Ratio Measurement To measure the lung wet-to-dry (W/D) weight ratio, mice were euthanized, and lung tissues were rapidly excised. The freshly isolated lungs were immediately weighted to obtain the wet weight. Subsequently, the tissues were placed in a drying oven at 60 °C for 72 h to determine the dry weight. The W/D weight ratio was calculated by dividing the wet weight by the corresponding dry weight. Enzyme-Linked Immunosorbent Assay (ELISA) The levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) were quantified using commercially available ELISA kits according to the manufacturers’ instructions (Elabscience Biotechnology Inc., Wuhan, China). Briefly, BALF were collected and centrifuged to remove debris. Samples and standards were added to 96-well plates pre-coated with capture antibodies and incubated at 37°C for the recommended time. After washing, biotinylated detection antibodies were added, followed by horseradish peroxidase (HRP)-conjugated streptavidin. Subsequently, tetramethylbenzidine substrate solution was added for color development in the dark, and the reaction was terminated with stop solution. Absorbance was measured at 450 nm using a microplate reader. Concentrations of TNF-α and IL-6 were calculated from standard curves. Measurement of Intracellular ROS Levels Intracellular ROS levels were measured using the reactive oxygen species assay kit (Beyotime Biotechnology, Shanghai, China) following the manufacturer’s instructions. Briefly, cells were incubate with diluted DCFH-DA probe at 37 °C for 20 min in the dark, then washed to remove extracellular dye. Fluorescence intensity was immediately quantified by flow cytometry (BD AccurTM C6 Plus, BD Biosciences, San Jose, CA, USA). Measurement of SOD, GSH/GSSG, MDA MDA, SOD and GSH/GSSG were measured by MDA assay kits (Beyotime Biotechnology, Shanghai, China), SOD assay kits (Beyotime Biotechnology, Shanghai, China) and GSH/GSSG assay kits (Beyotime Biotechnology, Shanghai, China), respectively, according to the manufacturer’s instructions. Immunohistochemistry (IHC) for MPO Tissue samples were fixed in 4% paraformaldehyde, paraffin-embedded, and sectioned to a thickness of 4 μm. The slides were deparaffinized with xylene and rehydrated through a graded ethanol series. Antigen retrieval was performed in citrate buffer (pH 6.0). Endogenous peroxidase activity was blocked by incubating the sections with 3% hydrogen peroxide, followed by blocking non-specific binding with 5% bovine serum albumin. The sections were then incubated with a primary anti-MPO antibody overnight at 4 °C. After washing with PBS, an HRP-conjugated secondary antibody was applied for 1 hour at room temperature. Immunoreactivity was visualized using a DAB substrate kit, and nuclei were counterstained with hematoxylin. Cell Cultures and Reagents Primary mouse pulmonary microvascular endothelial cells (PMVECs) were obtained from Fuheng Biology (Shanghai, China) and cultured in mouse vascular endothelial cell complete medium (Fuheng Biology, Shanghai, China). Cells were maintained at 37 °C in a humidified incubator with 5% CO2. All cell cultures were routinely tested and confirmed to be free of mycoplasma contamination. Cell Viability Assay Cell viability was assessed using a cell counting kit-8 (CCK-8) assay (Beyotime Biotechnology, Shanghai, China) following the manufacturer’s protocol. Briefly, cells were cultured in 96 well plates and incubated overnight. After treatment, 10 μL of CCK-8 reagent was added to each well, and the plates were incubated at 37 °C for 1–2 hours. Absorbance at 450 nm was measured using a microplate reader. Cell viability was calculated as a percentage of the control group. Cell Apoptosis Assay Cell apoptosis was evaluated using an FITC Annexin V apoptosis detection kit (BD Biosciences, NJ, USA) following the manufacturer’s guidelines. Cells were harvested, washed twice with cold PBS, and then resuspended in binding buffer to a final concentration of 1×106 cells/mL. To this suspension, 5 µL of FITC Annexin V and 5 µL of propidium iodide were added, and the mixture was incubated for 15 minutes at room temperature in the dark. Apoptotic cells were analyzed using a Beckman CytoFLEX S flow cytometer (Beckman Coulter, CA, USA). Cell ICAM-1 and VCAM-1 Detection Assay Cells were harvested, washed twice with cold PBS, and then resuspended in binding buffer to a final concentration of 1×106 cells/mL. To this suspension, 5 µL of FITC ICAM-1 (Selleck Chemicals, Houston, TX, USA, G1111) or FITC VCAM-1 (ABclonal Technology, Wuhan, China, A25748) were added, and the mixture was incubated for 15 minutes at room temperature in the dark. Cellular fluorescence was analyzed using flow cytometer (BD AccurTM C6 Plus, BD Biosciences, San Jose, CA, USA). Immunofluorescence Staining For immunofluorescence staining, tissues or cells were fixed in 4% paraformaldehyde for 15 min before permeabilizing with 0.5% Triton X-100 for 20 min and blocking with 4% goat serum for 30 min. Samples were incubated with primary antibody (1: 100) at 4 °C overnight followed by mouse or rabbit secondary antibody conjugated to a fluorescent marker (1: 2000) incubation. Images were collected under fluorescent microscope. Mitochondrial Membrane Potential (MMP) MMP was quantified using JC-1 staining and an MMP detection kit (Beyotime Biotechnology, C2003S). Briefly, the cells were washed by PBS and further incubated with the JC-1 staining at 37 °C for 30 minutes, followed by an additional 30 minute incubation with fresh medium in the dark. Fluorescence images were captured using a fluorescence microscope for analysis. Mitochondrial Permeability Transition Pore (mPTP) Opening Measurement MPTP opening was assessed using an mPTP assay kit (Beyotime Biotechnology, C2009S). After PBS washing, cells were incubated with the staining solution at 37 °C for 30 min, followed by an additional 30 min incubation in fresh medium in the dark. Fluorescence was then observed under a fluorescence microscope. Proteomics Analysis Proteins were extracted from samples using 8M urea buffer, followed by trypsin digestion. The resulting peptides were analyzed using LC-MS/MS on a Q Exactive HF-X Orbitrap mass spectrometer, with a 25 cm C18 column for separation. The data were processed with Spectronaut software, using the Mus musculus Uniprot database. Protein identification and quantification were performed with a 1% false discovery rate (FDR). The data were normalized using a local regression model, and functional annotation was conducted through Gene Ontology (GO) and KEGG databases to identify enriched pathways. Transcriptomics Analysis Total RNA was extracted and quality assessed using NanoDrop and electrophoresis. mRNA was purified and fragmented, followed by cDNA synthesis using the TruSeq Stranded mRNA Library Prep Kit. The libraries were sequenced on the NovaSeq 6000 platform. Raw data were processed using FastQC, and low-quality reads were removed with cutadapt. Clean reads were aligned to the reference genome with HISAT2, and transcript assembly was performed with StringTie. Gene expression was quantified using FPKM. Differential expression was analyzed with DESeq2, considering |log2 fold change| > 1 and FDR ≤ 0.05. GO and KEGG enrichment analyses were performed to identify biological functions and pathways. Metabolomics Analysis Metabolites were extracted from biological samples by adding 500 μL of precooled methanol containing internal standards to 100 μL of each sample, followed by vortex mixing and centrifugation. The supernatant was lyophilized and stored at −20°C. For quality control, an equal volume of all samples was mixed. LC-MS/MS analysis was performed using a Thermo Q Exactive HF-X mass spectrometer coupled with a Thermo Ultimate 3000 chromatography system. Both positive and negative ion modes were used for data acquisition. Chromatographic separation was achieved using Waters HSS T3 columns. Data were analyzed using Compound Discoverer software, where peak alignment, extraction, and quantification were performed. Metabolite identification and annotation were achieved by comparing with databases such as mzCloud and Chemspider. Differentially expressed metabolites (DEMs) were analyzed using fold-change, p-values, and VIP scores, followed by KEGG pathway enrichment analysis. Statistical Analysis Statistical analysis was performed using GraphPad Prism 8.02 (GraphPad Software, CA). The student’s t-test was used to assess differences between two groups, while one-way ANOVA was applied for comparisons among three or more groups. Survival analysis was conducted using the Kaplan-Meier method, with group differences evaluated by the log-rank (Mantel-Cox) test. Results from three independent experiments are presented as the Mean ± Standard Deviation (SD) or Mean ± Standard Error of the Mean (SEM). Statistical significance was defined as P < 0.05, with P values indicated on the plots (*P < 0.05; **P < 0.01). Results Physicochemical Characterization and Stability of BR@Lipo and BR@Lipo-CerTP Transmission electron microscopy images showed that both the unmodified liposomes (BR@Lipo) and the lung-targeting peptide–modified liposomes (BR@Lipo-CerTP) exhibited a regular spherical morphology with uniform size distribution and intact structural integrity (Figure 1A and B). Based on TEM analysis, BR@Lipo and BR@Lipo-CerTP exhibit a size range of 98.33 ± 32.26 nm and 102 ± 20.73 nm. Dynamic light scattering (DLS) analysis revealed that the average hydrodynamic diameter (Dh) of BR@Lipo was 120.10 ± 0.63 nm with a polydispersity index (PDI) of 0.213 ± 0.027, whereas BR@Lipo-CerTP displayed a slightly larger diameter of 123.03 ± 3.10 nm with a PDI of 0.218 ± 0.017 (Figure 1C–E). The comparable particle sizes and narrow distributions indicate that surface modification with the lung-targeting peptide did not significantly affect the size homogeneity or dispersity of the liposomes. The surface charge of the liposomes was further characterized by zeta potential measurements. The results showed that BR@Lipo possessed a zeta potential of −33.60 ± 4.55 mV, while BR@Lipo-CerTP exhibited a zeta potential of −35.17 ± 1.05 mV (Figure 1F). Both formulations carried strong negative surface charges, which contribute to maintaining colloidal stability through electrostatic repulsion and help prevent particle aggregation. EE (%) of BR@Lipo and BR@Lipo-CerTP are 87.28 ± 1.074% and 84.73 ± 2.33%, respectively. DL (%) of BR@Lipo and BR@Lipo-CerTP are 1.415 ± 0.017% and 1.374 ± 0.037%, respectively. To evaluate storage stability, the two liposomal formulations were dispersed in PBS or PBS containing 10% fetal bovine serum (FBS) and incubated at 37°C for 14 days, after which their particle size and PDI were measured. The results demonstrated no significant changes in particle size or PDI in either medium (Figure 1G and H), indicating excellent colloidal stability and serum tolerance. The cumulative percentage of BR detected in the release medium of BR exhibited distinct kinetics depending on the formulation. Free BR showed rapid diffusion across the dialysis membrane, with >85% detected within 48 h and >90% detected by 72 h, consistent with the absence of a carrier-mediated retention effect. In contrast, BR@Lipo displayed a biphasic release pattern: an initial burst release of ~15% within the first 4 h, followed by a sustained, gradual release reaching ~38% at 72 h. Notably, BR@Lipo-CerTP demonstrated significantly enhanced retention and delayed release, with only ~10% released in the first 4 h and a total cumulative release of ~35% after 72 h (Figure 1I). These findings support the suitability of the formulations for subsequent in vivo applications. Physicochemical Characterization and Stability of BR@Lipo and BR@Lipo-CerTP. (A and B) TEM image showing the monodisperse spherical morphology (scale bar: 100 nm). (C and D) Hydrodynamic size distribution measured by DLS. (E) Quantitative DLS analysis: average diameter and polydispersity index (PDI). (F) Zeta potential measurement. (G) Hydrodynamic diameter and PDI of BR@Lipo and BR@Lipo-CerTP in PBS (pH 7.4) at 37°C over 14 days. (H) Hydrodynamic diameter and PDI of BR@Lipo and BR@Lipo-CerTP in 10% FBS at 37°C over 14 days. (I) In vitro cumulative release profiles of free BR, BR@Lipo, and BR@Lipo-CerTP over 72 h. Values are shown as mean ± SD, *P < 0.05; **P < 0.01. Enhanced Cellular Uptake of BR@Lipo-CerTP in PMVECs As the pulmonary endothelial cells are the target cells of BR@Lipo-CerTP, PMVECs were chosen to evaluate the cytotoxicity effect in vitro using the standard CCK-8 assay. Free BR, BR@Lipo, and BR@Lipo-CerTP all demonstrated favorable biocompatibility, with cell viability remaining above 80% after 24 h incubation across the tested concentration range (Figure 2A–C). To investigate whether modification with the lung-targeting peptide enhanced intracellular delivery, cellular uptake studies were performed. A hydrophobic fluorescent probe (DiI) was co-encapsulated with BR during nanoparticle preparation to label the nanocarriers (BR@Lipo and BR@Lipo-CerTP).27 DLS analysis revealed that the average Dh of DiI-labeled BR@Lipo was 139.6 ± 1.4 nm with a PDI of 0.221 ± 0.014, while that of DiI-labeled BR@Lipo-CerTP was 155.5 ± 3.9 nm with a PDI of 0.225 ± 0.015 (Figure 2D and E). The zeta potential of DiI-BR@Lipo-CerTP was −32.0 ± 1.5 mV, and that of DiI-BR@Lipo was −28.7 ± 1.6 mV (Figure 2F). Fluorescence microscopy revealed time-dependent intracellular accumulation of DiI (red) in PMVECs, with nuclei counterstained by DAPI (blue). Notably, BR@Lipo-CerTP exhibited markedly stronger fluorescence signals in the cytoplasm compared with BR@Lipo over a 4 h incubation period (Figure 2G). These qualitative observations were further confirmed by quantitative flow cytometry analysis. Both formulations showed a gradual increase in cellular internalization over time; however, the uptake rate of BR@Lipo-CerTP was significantly higher than that of BR@Lipo (Figure 2H and I). Cellular uptake kinetics of BR@Lipo and BR@Lipo-CerTP in PMVECs. (A–C) Dose-response of PMVECs treated with gradient concentrations of free BR, BR@Lipo or BR@Lipo-CerTP for 24 h. Cell viability was quantified by CCK-8 assay. (D) Hydrodynamic size distribution measured by DLS. (E) Quantitative DLS analysis: average diameter and PDI. (F) Zeta potential measurement. (G) Fluorescence microscope images of PMVECs incubated with DiI-labeled BR@Lipo and BR@Lipo-CerTP (BR@Lipo and BR@Lipo-CerTP, 2 μM BR equivalent) for 1, 2, and 4 h. Nuclei were counterstained with DAPI (blue). Red fluorescence indicates DiI localization. Scale bar, 100 μm. (H and I) Flow cytometric quantification of time-dependent nanoparticle internalization. Values in (A-C, I) are shown as mean ± SEM and in (D-F) are shown as mean ± SD, *P < 0.05; **P < 0.01. Protective Effects of BR@Lipo-CerTP in PQ-Induced Cytotoxicity and Cell Dysfunction in PMVECs To evaluate the protective effect of BR@Lipo-CerTP on PMVECs, we first performed a dose-ranging study to assess its cytotoxicity and determine the optimal concentration. CCK-8 assays showed that PQ markedly decreased cell viability, whereas co-treatment with BR@Lipo-CerTP significantly restored cell viability in a dose-dependent manner. Free BR and BR@Lipo also improved cell viability to some extent, but their protective effects were weaker than those of BR@Lipo-CerTP (Figure 3A). These findings were further corroborated by Calcein-AM/PI double staining, which revealed that the PQ group exhibited the lowest proportion of viable cells, while the BR@Lipo-CerTP group displayed the highest proportion of live cells among all treatment groups (Figure S1). Annexin V/PI staining further demonstrated that PQ exposure significantly increased the apoptotic rate of PMVECs. This increase was attenuated by Free BR, BR@Lipo, and BR@Lipo-CerTP treatment, with BR@Lipo-CerTP showing the greatest reduction in apoptosis among the treatment groups (Figure 3B and C). While BR@Lipo group did not significantly differ from the free BR group in apoptosis rate. Consistent with these findings, TUNEL staining revealed that PQ-induced apoptotic cell death was significantly decreased following BR-based treatments, and the BR@Lipo-CerTP group exhibited the lowest proportion of TUNEL-positive cells (Figure 3D). Furthermore, the expression levels of endothelial activation markers ICAM-1 and VCAM-1 were evaluated; PQ exposure markedly upregulated both proteins, and this upregulation was most effectively reversed by BR@Lipo-CerTP (Figure 3E and F). Together, these results indicate that Free BR, BR@Lipo, and BR@Lipo-CerTP all alleviate PQ-induced cytotoxicity, apoptosis, and endothelial activation in PMVECs, with BR@Lipo-CerTP exerting the strongest protective effect. Protective function of BR@Lipo-CerTP in PQ-induced cell damage. (A) Dose-response of PMVECs treated with PQ (800 μM) and different concentrations of free BR, BR@Lipo or BR@Lipo-CerTP for 24 h. (B and C) PMVECs were treated with free BR, BR@Lipo or BR@Lipo-CerTP (2 μM BR eq.) for 2 h before stimulating with PQ (800 μM) for 24 h, and then cell apoptosis was determined by Annexin V-FITC/PI flow cytometry. (D) PMVECs were treated with free BR, BR@Lipo or BR@Lipo-CerTP (2 μM BR eq.) for 2 h before stimulating with PQ (800 μM) for 24 h, and then cell fluorescence was detected under a fluorescence microscope. Scale bar, 100 μm. (E and F) PMVECs were treated with free BR, BR@Lipo or BR@Lipo-CerTP (2 μM BR eq.) for 2 h before stimulating with PQ (400 μM) for 24 h, and then flow cytometric quantification of ICAM-1 and VCAM-1 of cells was conducted. Values are shown as mean ± SEM, *P < 0.05; **P < 0.01. BR@Lipo-CerTP Reduces ROS and Protects Mitochondrial Function in PQ-Stimulated PMVECs To evaluate whether BR@Lipo-CerTP exerted consistent protective effects on endothelial cells in vitro, PMVECs were pretreated with free BR, BR@Lipo, BR@Lipo-CerTP, or PBS, followed by exposure to PQ (400 μM) for 24 h. Intracellular ROS levels and mitochondrial function related parameters were subsequently assessed. PQ stimulation markedly increased ROS production in PMVECs, whereas pretreatment with free BR, BR@Lipo, or BR@Lipo-CerTP significantly attenuated this elevation. Notably, BR@Lipo-CerTP demonstrated a superior ROS-scavenging effect compared with free BR and BR@Lipo (Figure 4A and B). In parallel, PQ exposure decreased relative SOD activity and the GSH/GSSG ratio, while all BR formulations restored these antioxidant indices. The restorative effect was most pronounced in the BR@Lipo-CerTP group (Figure 4C and D). Then we investigated function of mitochondria in PMVECs. JC-1 staining demonstrated a reduced polymer-to-monomer ratio following PQ treatment; however, BR@Lipo-CerTP preserved MMP (ΔΨm) (Figure 4E). Fluorescence microscopy was employed to assess calcein-AM retention in mitochondria, aiming to evaluate if oxidative stress triggers mPTP opening in PQ-treated PMVECs. A decrease in calcein-AM retention indicated mPTP opening and increased mitochondrial permeability, which was significantly reduced by BR@Lipo-CerTP (Figure 4F). BR@Lipo-CerTP Reduces ROS and Protects Mitochondrial Function in PQ-Stimulated PMVECs. PMVECs were treated with free BR, BR@Lipo or BR@Lipo-CerTP (2 μM BR eq.) for 2 h before stimulating with PQ (400 μM) for 24 h, and then (A and B) cell ROS was measured by DCF flow cytometry. (C and D) cell SOD and GSH/GSSH were determined by relevant detection kit. (E) cell MMP was determined by a fluorescence microscope. Scale bar, 100 μm. (F) cell calcein AM/Co2+ fluorescence intensity was measured by a fluorescence microscope. Scale bar, 100 μm. Values are shown as mean ± SEM, *P < 0.05; **P < 0.01. Potential Mechanism in the Protection of BR@Lipo-CerTP in PQ-Induced Cell Damage To explore the underlying mechanisms, we performed multi-omics analyses, including proteomics, transcriptomics, and metabolomics, for both the PQ+BR@Lipo-CerTP and PQ groups. Proteomic analysis identified 321 differentially expressed genes (DEGs), with 157 upregulated and 164 downregulated genes in BR@Lipo-CerTP-treated PMVECs (Figure 5A). GO enrichment analysis revealed significant associations with over 20 biological pathways, particularly those related to glutathione metabolism, oxidative stress response, and ferroptosis regulation, all crucial for cellular survival under oxidative stress (Figure 5B). KEGG analysis further confirmed enrichment in pathways related to ubiquinone biosynthesis, glutathione metabolism, and ferroptosis (Figure 5C). Transcriptomics identified 1242 DEGs, with 481 upregulated and 761 downregulated genes in the BR@Lipo-CerTP group (Figure 5D). KEGG pathway analysis highlighted enrichment in anti-inflammatory pathways, including NOD-like, TNF and TOLL-like receptor signaling pathway (Figure 5E). Integrated analysis of transcriptomics and proteomics revealed enrichment in ROS, oxidative phosphorylation, and glutathione metabolism pathways (Figure 5F). Metabolomics analysis showed differential quantification of 182 metabolites, with 109 increased and 73 decreased in the PQ+BR@Lipo-CerTP group compared to the PQ group (Figure 5G). KEGG pathway analysis suggested an enrichment in unsaturated fatty acid biosynthesis (Figure 5H). Thus, multi-omics analyses revealed that BR@Lipo-CerTP treatment modulates key pathways involved in oxidative stress, cell death and inflammation, potentially explaining its protective effect against PQ-induced cellular damage. Multi-omics Analysis Reveals Protective Mechanisms of BR@Lipo-CerTP in PQ-Induced Oxidative Damage. PMVECs were treated with PBS or BR@Lipo-CerTP (2 μM BR eq.) for 2 hours prior to stimulation with PQ (400 μM) for 24 hours, followed by multi-omics analysis. n = 3. (A) Volcano plot of differentially expressed genes (DEGs) from proteomics. (B) GO enrichment bubble plot showing the top 20 significantly enriched terms in the biological process (BP), molecular function (MF), and cellular component (CC) categories of proteomics. (C) KEGG pathway enrichment analysis for the top 20 significantly enriched pathways of proteomics. (D) Volcano plot of DEGs from transcriptomics. (E) KEGG pathway enrichment analysis for the top 20 significantly enriched pathways of transcriptomics. (F) KEGG pathway enrichment analysis for the top 20 significantly enriched pathways from integrated proteomics and transcriptomics analysis. (G) Volcano plot of DEMs from metabolomics. (H) KEGG pathway enrichment analysis for the top 20 significantly enriched pathways in metabolomics. Protective Effects of BR@Lipo-CerTP in PQ-Induced ALI in Mice Prior to assessing in vivo therapeutic efficacy, we employed fluorescence imaging to evaluate the biodistribution and pulmonary targeting capacity of BR@Lipo-CerTP relative to BR@Lipo. Compared to BR@Lipo, BR@Lipo-CerTP exhibited significantly enhanced accumulation in the lungs (Figure 6A–C). In vivo and ex vivo fluorescence imaging for verifying the lung targeting ability and distribution. (A) Representative in vivo fluorescence images of ALI mice after tail vein injectection (i.v.) with 100 μL DiR-labeled BR@Lipo or BR@Lipo-CerTP after 12 h. (B) Ex vivo fluorescence imaging in the heart (H), liver (Li), spleen (Sp), lung (Lu), and kidney (Ki) at 12 h after i.v. injection of BR@Lipo or BR@Lipo-CerTP. (C) Fluorescence quantitative analysis of main organs from mice. Values are shown as mean ± SEM, *P < 0.05; **P < 0.01. To evaluate the protective effects of different BR formulations in PQ-induced ALI, we assessed various parameters associated with ALI. Free BR exhibits extremely poor water solubility and rapid systemic clearance, making intravenous administration impractical due to the risk of precipitation and embolism; therefore, oral gavage was selected as the clinically relevant reference route that aligns with current standard practice. In contrast, BR@Lipo and BR@Lipo-CerTP demonstrate excellent colloidal stability in serum without drug leakage or precipitation, enabling safe and effective intravenous delivery to achieve enhanced lung targeting and bioavailability. Therefore, tail vein injection was selected as the route of administration for BR@Lipo and BR@Lipo-CerTP. As shown in Figure 7A, treatment with free BR, BR@Lipo, and BR@Lipo-CerTP all improved the survival of PQ-poisoned mice compared with the PQ group, with BR@Lipo-CerTP showing the strongest protective effect. At 48 h after sublethal PQ exposure, gross examination of the isolated lungs showed severe hemorrhage and edema in the PQ group, whereas these pathological changes were alleviated by BR treatment, particularly by BR@Lipo-CerTP (Figure 7B). Consistently, the increased wet-to-dry ratio of lung tissue induced by PQ was significantly reduced after BR formulation treatment (Figure 7C), indicating attenuation of pulmonary edema. In BALF, PQ exposure markedly elevated LDH, total protein, IL-6, and TNF-α levels, while these increases were significantly suppressed by BR treatment, especially in the BR@Lipo-CerTP group (Figure 7D–G). These results suggested that BR@Lipo-CerTP effectively reduced alveolar-capillary barrier damage and inflammatory responses in PQ-injured lungs. We further assessed oxidative stress in lung tissues and found that PQ markedly increased MDA levels and decreased SOD activity, whereas BR@Lipo-CerTP treatment reversed these changes (Figure 7H and I), indicating effective suppression of PQ-induced oxidative injury. Histological examination by H&E staining revealed extensive alveolar structure destruction, inflammatory cell infiltration, and interstitial thickening in the PQ group, all of which were notably ameliorated by BR@Lipo-CerTP treatment (Figure 7J). In addition, immunohistochemical staining showed increased MPO-positive signals in PQ-treated lungs, indicating enhanced neutrophil infiltration, while BR@Lipo-CerTP markedly reduced MPO expression (Figure 7K). TUNEL staining further demonstrated that PQ induced substantial apoptosis in lung tissue, whereas BR@Lipo-CerTP significantly decreased the number of TUNEL-positive cells (Figure 7L). Together, these findings demonstrate that BR@Lipo-CerTP exerts a pronounced protective effect against PQ-induced ALI by reducing pulmonary edema, inflammation, oxidative stress, neutrophil infiltration and apoptosis. Protective function of BR@Lipo-CerTP in PQ-induced lung injury. (A) C57/BL6 mice were i.p. with a lethal dose (70mg/kg) (A) (n = 10 mice/group) or a sublethal dose (50mg/kg) (B–K) (n = 3–7 mice/group) of PQ after i.v. with PBS, gavage with free BR (5 mg/kg) 30 min earlier, i.v. with BR@Lipo or BR@Lipo-CerTP (BR 5 mg/kg) 30 min later. (A) Mouse survival was observed every 12 h up to 96 h. After 48 h, (B) representative photographs of ex vivo mouse lungs were taken. (C) wet/dry ratio of lung tissue was measured. (D) LDH, (E) total protein, (F) IL-6, (G) TNF-α were determined in the bronchial alveolar lavage fluid (BALF). (H and I) MDA and SOD were measured in lung tissue. (J) H&E staining of lung sections. (K) IHC staining of MPO in mouse lung tissue sections. (L) Immunofluorescence analysis of DAPI and TUNEL in mouse lung sections. Values are shown as mean ± SEM, *P < 0.05; **P < 0.01. In vivo Biosafety of BR@Lipo-CerTP Both short-term and long-term in vivo biosafety of these formulations were further assessed in healthy mice. No mortality occurred during the 3-day or 14-day observation period (Figures 8A and S2A). Hematological parameters, including white blood cells (WBC), red blood cells (RBC), and platelets (PLT), as well as biochemical indicators of liver and kidney function, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl transferase (γ-GT), blood urea nitrogen (BUN), creatinine (Crea), and uric acid (UA), remained within normal ranges on day 3 and day 14, suggesting no impairment of hematopoietic, hepatic, or renal function (Figures 8B–H and S2B–H). Consistent with the blood analysis, histopathological evaluation of major organs (heart, liver, spleen, lung, and kidney) revealed intact tissue architecture without evident inflammatory infiltration or structural abnormalities (Figures 8I and S2I). Collectively, these findings indicate that BR@Lipo-CerTP does not elicit detectable acute or chronic toxicity, either locally or systemically, and exhibits excellent in vivo biosafety. Biosafety of BR@Lipo-CerTP in vivo. C57/BL6 mice were i.v. with PBS, gavage with free BR (5 mg/kg), i.v. with BR@Lipo or BR@Lipo-CerTP (BR 5mg/kg) (n = 3 mice/group). (A) Mice survival rate was observed every 24 h up to 3 d. (B–I) After 72 h, mice were sacrificed, and blood samples, heart, liver, spleen, lung, and kidney tissues were collected. (B) Red blood cell, white blood cell, and platelet count in mouse blood samples. (C–H) ALT, AST, γ-GT, BUN, Crea and UA levels in mouse blood samples. (I) H&E staining of heart, liver, spleen, lung, and kidney sections. Values are shown as mean ± SEM, *P < 0.05; **P < 0.01. Discussion Exposure to PQ is widely recognized as a major cause of severe and often fatal pulmonary toxicity. Following systemic absorption, PQ exhibits a strong propensity to accumulate in lung tissue via the polyamine uptake system in endothelial cells and alveolar epithelial cells. Within these cells, PQ undergoes continuous redox cycling, leading to excessive generation of ROS. The resulting oxidative stress compromises membrane integrity, increases vascular permeability, promotes pulmonary edema, and ultimately impairs gas exchange.5,28 Therefore, scavenging ROS in endothelial and alveolar epithelial cells represents a promising therapeutic strategy for PQ-induced ALI. Free bilirubin exhibits narrow therapeutic windows due to its potential neurotoxicity at supraphysiological concentrations, a risk that has historically limited its systemic application. Rather than representing an inherent flaw of our approach, this safety concern directly motivated the rational design of BR@Lipo-CerTP. By conjugating CerTP peptide for active targeting to injured pulmonary endothelium, the nanosystem achieves higher lung accumulation compared to non-targeted controls, enabling effective local therapeutic concentrations while reducing systemic exposure. The results indicated that BR@Lipo-CerTP exhibited significantly improved cellular affinity compared to BR@Lipo, as evidenced by its higher uptake by pulmonary microvascular endothelial cells (Figure 2). Additionally, BR@Lipo-CerTP demonstrated reduced cytotoxicity in vitro compared to free BR, suggesting that this formulation offers a safer and potentially more effective approach for drug delivery. Furthermore, BR@Lipo-CerTP significantly attenuated PQ-induced oxidative damage and apoptosis, indicating its strong antioxidant and anti-apoptotic properties. Notably, BR@Lipo-CerTP showed superior therapeutic efficacy compared to both free BR and BR@Lipo, as demonstrated by its protective effects on mitochondrial function, including the preservation of mitochondrial membrane potential and the inhibition of mPTP opening, which are critical markers of cellular integrity under oxidative stress conditions (Figures 3 and 4). In the PQ-induced ALI mouse model, BR@Lipo-CerTP further demonstrated its pronounced lung protection. This was reflected in the increased survival rate, reduced pulmonary histopathological injury, and diminished oxidative damage. Additionally, BR@Lipo-CerTP decreased the exudation of protein-rich fluid and the production of pro-inflammatory cytokines, which are hallmarks of PQ-induced lung toxicity. These findings suggest that the CerTP-modified liposomes not only improve the delivery of BR but also enhance its therapeutic efficacy in a relevant animal model (Figure 7). Moreover, the biosafety assessment confirmed that free BR, BR@Lipo, and BR@Lipo-CerTP all exhibited good biocompatibility, further supporting the safety of these formulations for potential clinical applications (Figure 8). Targeting pulmonary endothelial cells has been widely recognized as a promising strategy for achieving precise therapeutic intervention in ALI. In the existing literature, several approaches have been explored to facilitate endothelial-specific delivery, including antibody-functionalized nanoparticles and peptide ligand-decorated nanocarriers.29,30 Among these strategies, peptide-based targeting ligands offer distinct advantages, particularly their relatively low synthetic cost and reduced immunogenicity, making them attractive candidates for the development of targeted nanomedicine systems.31,32 Several ligands capable of targeting pulmonary endothelial cells have been reported, including anti-ICAM-1 and anti-VCAM-1 antibodies, as well as lung-homing peptides.33,34 However, these targets are also expressed on endothelial cells in other organs, such as the brain, heart, and kidneys. Consequently, achieving precise lung-specific targeting remains challenging. A recent study reported that the VHPK peptide facilitates efficient drug delivery through specific targeting of VCAM-1, which is markedly upregulated in inflamed pulmonary tissue during acute lung injury.35 C16-ceramide is a recently identified lipid molecule predominantly expressed on pulmonary microvascular endothelial cells, with relatively low expression in endothelial cells from other vascular beds. Importantly, its expression is markedly elevated in several pulmonary diseases, including ARDS, COPD, and COVID-19.23 The cyclic lung-homing peptide CGSPGWVRC has been reported to specifically recognize and bind to C16-ceramide, thereby enabling selective targeting of pulmonary endothelial cells. Consistent with this mechanism, BR@Lipo-CerTP exhibited higher cellular affinity than BR@Lipo in our study and demonstrated superior therapeutic efficacy in both in vitro and in vivo models of paraquat-induced acute lung injury. Rather than treating glutathione metabolism, ferroptosis, and inflammatory signaling as isolated entities, our multi-omics data reveal a tightly interconnected regulatory axis that underpins the therapeutic mechanism of BR@Lipo-CerTP in PQ-induced cell damage. Specifically, PQ exposure triggers excessive ROS generation that directly depletes GSH, the central cofactor for GPX4 activity; this collapse of glutathione homeostasis serves as the primary molecular switch initiating ferroptotic lipid peroxidation.36 Concurrently, ferroptosis-derived damage-associated molecular patterns (DAMPs), particularly oxidized phospholipids and free iron, activate NF-κB and NLRP3 inflammasome pathways, amplifying neutrophil infiltration and cytokine release.37 Critically, this inflammatory cascade further exacerbates GSH depletion and accelerates ferroptosis. BR@Lipo-CerTP intervention disrupts this positive feedback loop at multiple nodes: by restoring intracellular GSH pools through its intrinsic antioxidant capacity; simultaneously, by scavenging lipid peroxides and chelating labile iron, it reduces DAMP-mediated inflammatory activation, thereby breaking the cycle of mutual amplification. This integrative crosstalk analysis demonstrates that the efficacy of BR@Lipo-CerTP arises not from modulating a single pathway, but from coordinately resetting the pathological equilibrium among redox, cell death, and immune responses. Compared with previously reported bilirubin delivery systems, the novelty of BR@Lipo-CerTP lies in the integration of bilirubin-loaded liposomes with a C16-ceramide-targeting peptide, enabling active targeting of injured pulmonary endothelium rather than relying solely on passive accumulation. Unlike conventional endothelial targets such as ICAM-133 or VCAM-1,38 C16-ceramide is preferentially enriched in pulmonary endothelial cells under inflammatory conditions, potentially improving lung specificity. Moreover, BR@Lipo-CerTP maintained favorable colloidal stability and significantly enhanced endothelial uptake and therapeutic efficacy compared with free BR and non-targeted liposomes. These findings suggest that CerTP-mediated pulmonary endothelial targeting represents a promising strategy to improve the precision and effectiveness of bilirubin-based therapy for oxidative lung injury. Despite the promising efficacy of BR@Lipo-CerTP in PQ-induced ALI, several limitations must be acknowledged before clinical translation. First, the inherent photosensitivity and chemical instability of BR necessitate strict light-shielding protocols to prevent premature degradation during administration.39,40 Second, as C16-ceramide can be upregulated systemically under severe inflammation,41 off-target accumulation remains a concern, warranting biodistribution studies in large animal models. Third, efficacy was evaluated only with early intervention administered 30 minutes before PQ exposure; however, given that patients in real-world clinical settings are often admitted hours after poisoning, the therapeutic efficacy under delayed dosing conditions and its potential for treating late-stage fibrotic poisoning remain to be verified.4,5 Fourth, while pulmonary accumulation correlated with C16-ceramide expression, direct mechanistic validation was not performed; thus, targeting should be considered C16-ceramide-associated rather than definitively mediated. Fifth, the surface grafting density of the targeting ligand on BR@Lipo-CerTP was not quantitatively determined; since ligand density critically governs receptor-binding avidity and the balance between active targeting and PEG-mediated steric hindrance, the absence of this parameter precludes precise optimization of the formulation and limits reproducibility across batches. Finally, the relatively small sample size in the murine experiments may limit the statistical power and generalizability of our findings, underscoring the need for validation in larger cohorts. Beyond PQ poisoning, the BR@Lipo-CerTP platform holds significant translational potential for other ROS-mediated pulmonary diseases. Pulmonary microvascular endothelial dysfunction and excessive ROS generation are central pathophysiological hallmarks shared by ARDS,42 COPD,43 and ventilator-induced lung injury.44 Importantly, C16-ceramide, the target of our CerTP peptide, has been reported to be markedly upregulated on pulmonary endothelial cells in ARDS and COPD patients,23 providing a conserved molecular anchor for targeted delivery across these etiologies. Future studies validating this platform in clinically relevant models of ARDS or COPD would be instrumental in establishing its versatility as a precision nanotherapeutic for oxidative lung injuries. Conclusion Taken together, our results demonstrate that CerTP-modified liposomal delivery of BR effectively attenuates PQ-induced acute lung injury by reducing oxidative stress, preserving mitochondrial function, and mitigating endothelial injury and inflammation. The superior efficacy of BR@Lipo-CerTP highlights the value of pulmonary endothelial cell-targeted nanodelivery in enhancing the therapeutic potential of BR (Figure 9). Rational design and pulmonary endothelial-targeted nanodelivery system of self-assembled BR@Lipo-CerTP. The modification of BR-loaded liposomes with a C16-ceramide-binding peptide enhances their targeted accumulation and uptake in pulmonary endothelial cells. BR@Lipo-CerTP effectively scavenges excessive ROS, restores cellular antioxidant capacity and mitochondrial function, inhibits apoptosis and inflammation, reduces pulmonary edema and tissue damage, and significantly improves survival in a PQ-induced ALI mouse model. Acknowledgments The authors would like to express their sincere gratitude to Dandan Song at the Center of Cryo-Electron Microscopy (CCEM), Zhejiang University, for her assistance in transmission electron microscopy imaging. Funding Statement This work was supported by the Natural Science Foundation of Zhejiang Province (Grant No. ZCLQ24H0101), National Natural Science Foundation of China under (Grant No. 82300101), “Innovation Yongjiang 2035” Key R&D Programme (Grant no. 2024Z230) and Natural Science Foundation of Ningbo City (Grant No. 2024J326). Highlights Engineered endothelial-targeted liposomes enhance bilirubin delivery to injured lungs. Engineered endothelial-targeted liposomes enhance bilirubin delivery to injured lungs. BR@Lipo-CerTP enhanced cellular uptake in pulmonary endothelial cells. BR@Lipo-CerTP enhanced cellular uptake in pulmonary endothelial cells. BR@Lipo-CerTP preserves mitochondrial function and reduces endothelial cell apoptosis. BR@Lipo-CerTP preserves mitochondrial function and reduces endothelial cell apoptosis. BR@Lipo-CerTP improved survival and alleviated lung injury in PQ mice. BR@Lipo-CerTP improved survival and alleviated lung injury in PQ mice. Multi-omics reveals modulation of oxidative stress, cell death, and inflammation pathways. Multi-omics reveals modulation of oxidative stress, cell death, and inflammation pathways. AI Statement The authors acknowledge the use of artificial intelligence technology, specifically ChatGPT (OpenAI), to assist with language editing and manuscript polishing. However, all scientific content, data interpretation, critical analysis, and final editorial decisions were made solely by the authors. The AI tool was not involved in the design of the study, data collection, or drawing of conclusions. The authors take full responsibility for the integrity and accuracy of the work. Data Sharing Statement The data that support the findings of this research are available from the corresponding author upon reasonable request. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure Mengyuan Cen and Tongyu Li are co-first authors for this study. The authors declare no financial, personal, or professional relationships with any individuals or organizations that could inappropriately influence or be perceived to influence our work. Furthermore, the authors have no interest of any nature or kind, in any product, service, or company that might be construed as affecting the objectivity or integrity of this manuscript. References Associated Data Data Availability Statement The data that support the findings of this research are available from the corresponding author upon reasonable request.